S-1/A: BioSig Technologies Files Amendment No. 1 to Form S-1 for Resale of Common Stock

BioSig Technologies files an amendment to its Form S-1 registration statement for the resale of up to 1,680,631 shares of common stock issuable upon the exercise of outstanding warrants.

Summary

• BioSig Technologies has filed Amendment No. 1 to its Form S-1 registration statement with the SEC.
• The filing concerns the resale of up to 1,680,631 shares of the company's common stock.
• These shares are issuable upon the exercise of outstanding warrants issued on May 30, 2024.
• The warrants were issued pursuant to securities purchase agreements dated May 29, 2024, and an engagement letter with H.C. Wainwright & Co., LLC.
• BioSig will not receive any proceeds from the sale of these shares by the selling stockholders.
• However, BioSig will receive the exercise price of the warrants if they are exercised for cash, totaling approximately $3,058,317.
• The selling stockholders may resell the shares through public or private transactions at prevailing market prices or negotiated prices.
• No underwriter has been engaged to facilitate the sale of the common stock.
• BioSig will bear all costs related to the registration of the common stock, while the selling stockholders will bear any commissions or discounts.
• The company's common stock is quoted on the OTCQB Marketplace under the symbol BSGM, with a last reported sales price of $0.50 per share on July 23, 2024.
• Investing in BioSig's common stock involves a high degree of risk.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on outlining the details of the share resale and associated warrants. While it mentions risks, it does not express overt optimism or pessimism.

Positives

• If warrants are exercised, BioSig will receive approximately $3,058,317.
• The registration allows selling stockholders flexibility in reselling shares.

Negatives

• BioSig will not receive any proceeds from the resale of shares by the selling stockholders.
• The company's common stock is currently trading at a low price of $0.50 per share.
• Investing in BioSig's common stock involves a high degree of risk.

Risks

• The selling stockholders may not offer or sell any of the registered shares.
• The market price of the common stock may fluctuate significantly.
• The company may need to raise additional capital in the future, which may not be available on favorable terms.
• The company is an early commercialization stage company and expects to incur substantial additional operating losses.
• The company's PURE EP System and other product candidates are in continued development and may not be successfully developed or commercialized.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's common stock is currently quoted on the OTCQB, which may have an unfavorable impact on its stock price and liquidity.

Future Outlook

The selling stockholders may offer or sell shares of common stock from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.

Industry Context

This announcement is typical for companies seeking to provide liquidity for existing warrant holders, allowing them to potentially profit from their investment while providing the company with potential future capital if the warrants are exercised.

Comparison to Industry Standards

• Comparable companies in the medical device industry, such as Medtronic, Boston Scientific, and Abbott, often utilize similar registration statements to facilitate the resale of securities by existing shareholders.
• The terms of the warrants, including the exercise price and expiration date, are generally consistent with industry standards for similar types of financing transactions.
• The fees and expenses associated with the registration and potential sale of the common stock are also within the typical range for such transactions.

Stakeholder Impact

• Existing shareholders may experience dilution if the warrants are exercised and new shares are issued.
• The resale of shares by selling stockholders could potentially impact the market price of the common stock.
• The company's ability to fund its operations and execute its business plan depends on its ability to raise capital.

Next Steps

• Selling stockholders may offer or sell shares of common stock from time to time.
• The company may receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash.
• The company intends to use those proceeds, if any, for working capital and general corporate purposes.

Key Dates

Keywords

common stock, warrants, resale, BioSig Technologies, securities, offering, BSGM, OTCQB, registration statement